

VintaBio Names Jennifer Kingsley Chief Commercial Officer



VintaBio, a life sciences company with unmatched industry expertise in helping alleviate the viral vector bottleneck in cell and gene therapy (CGT) development, named Jennifer Kingsley as its first Chief Commercial Officer to develop and implement the company's commercial strategy. With 25 years of life science commercial experience, including the past decade at Cytiva, Kingsley is poised to lead VintaBio through rapid growth following its unveiling as a premier CGT contract development and manufacturing organization (CDMO) earlier this year.

"Jennifer's strategic commercial and business development leadership and experience will be key as we demonstrate to potential partners the value of finding the right CDMO for their clinical scale-up, from proof-of-concept through regulatory filings," said David Radspinner, VintaBio's CEO. "We're excited to have her join our fast-growing team with unrivaled experience, including the pioneers who developed the vectors that power some of the first commercial cell and gene therapies."

At Cytiva, Kingsley was most recently Commercial Zone Leader, responsible for leading a global team as it transitioned to a transformative digital supply chain and delivered more than \$20 million in new business for the company. She previously served as Cytiva's Executive Account Director of Global Strategic Accounts. Before joining Cytiva, Kingsley worked in commercial positions at Sigma-Aldrich and Life Technologies/Invitrogen, before its acquisition by Thermo Fisher Scientific.

"This is a great moment to join a world-class team of manufacturing experts, as the cell and gene therapy space is poised to explode," said Kingsley. "I'm looking forward to building the sales and marketing teams that will propel VintaBio forward through an increasingly noisy space."

VintaBio also hired Ann Lee as Chief of Staff. Ann has more than a decade of experience helping found and grow life sciences companies, most recently as Chief of Staff and VP Strategic Affairs for medtech company Zuko, Inc.

Source: VintaBio

Published on : Wed, 16 Aug 2023